NCT02747199已完成不适用
Comparison Between SYNERGY™ vs. Bioresorbable Vascular Scaffold (BVS) ABSORB Neointimal Formation Assessed by (Optical Coherence Tomography) OCT and Coronary Angioscopy (CAS) Evaluation (The ENHANCE Study - ENdothelial Healing Assessment With Novel Coronary tEchnology)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 主要终点
- Apposition and neointimal coverage on the stent and scaffold strut
研究概览
简要总结
This is a prospective, non-randomized, single center clinical trial to assess neointimal coverage on the stent or scaffold strut and apposition of SYNERGY™ and ABSORB in minimum of 12 eligible human subject at 4 month and 12 month after stent or scaffold implantation using OCT and CAS
详细描述
All of the subject will received SYNERGY™ stent in one of the blocked coronary artery and ABSORB scaffold strut in the other artery. All subjects must have 2 coronary arteries stenosis of more than 70%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is 20 years old or older
- •Subject or legally authorized representative must provide written informed consent prior to any study related procedure, per site requirements.
- •Subject must have evidence of myocardial ischemia (eg stable or unstable angina, silent ischemia) suitable for elective PCI
- •Significant narrowing of at least 70% stenosis of de novo lesion (QCA or visual estimation) in 2 different native coronary arteries.
- •Subject is eligible for to undergo OCT and CAS examination at 4 months and 12 months after stent or scaffold implantation.
- •Subject is able to take dual anti-platelet therapy up to one year following the index procedure and anticoagulants prior/during the index procedure
排除标准
- •Subject had an acute myocardial infarction (STEMI or NSTEMI) within 24 hours of the index procedure
- •Subject has known left ventricular ejection fraction (LVEF) < 30%
- •Subject is receiving hemodialysis
- •Target vessel were treated by PCI within 12 months
- •Target lesion is located within a saphenous vein graft or an arterial graft
- •Target lesion is located in ostium
- •Target lesion is located highly tortuous equal to or greater than 60 degrees
- •Target lesion with TIMI flow 0 (total occlusion)
结局指标
主要结局
Apposition and neointimal coverage on the stent and scaffold strut
时间窗: 4 months
Neointimal coverage on the stent and scaffold strut and their apposition using OCT and CAS at 4 month after the stent implantation.
次要结局
- Apposition and neointimal coverage on the stent and scaffold strut(12 months)
研究者
Wan Azman Wan Ahmad
Professor Dr
University of Malaya
相似试验
Unknown
不适用
Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)Coronary StenosisNCT02421016Deutsches Herzzentrum Muenchen230
Unknown
不适用
NeoVas Bioresorbable Coronary Scaffold Registry StudyCoronary Artery DiseaseNCT02305472Lepu Medical Technology (Beijing) Co., Ltd.825
进行中（未招募）
不适用
The OCT SORT-OUT VIII StudyMyocardial InfarctionAngina PectorisCoronary Artery DiseaseNCT02253108Aarhus University Hospital Skejby160
暂停
不适用
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISRCoronary RestenosisCoronary Artery DiseaseNCT02474485SIS Medical AG53
Unknown
不适用
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled TrialCoronary Artery DiseaseNCT02305485Lepu Medical Technology (Beijing) Co., Ltd.560